Coronado Biosciences Inc (NASDAQ:CNDO) Fourth Quarter Results

691

Dallas, Texas 03/19/2014 (FINANCIALSTRENDS) –  Burlington-based Coronado Biosciences Inc (NASDAQ:CNDO), is the immunotherapy developer where the biological agents are optimized to treat autoimmune diseases as well as cancer. The lead candidates for this biopharmaceutical company are – Trichurissuis ova, technically called CNDO-201, which is a biologic using microscopic eggs to treat diseases of the autoimmune variety.

These include diseases such as Crohn’s disease, ulcerative colitis or UC as well as multiple-sclerosis. CNEO-109, which is a compound that moves natural killer cells in the immune system to destroy as well as seek cancer cells to treat acute myeloid leukemia or AML.

Fourth quarter and full year results

Coronado Biosciences Inc(NASDAQ:CNDO) has posted financial results for the fourth quarter as well as the year end results for 2013. Presenting the results was the Chairman of the company, Dr.Lindsay A. Rosenwald. The results of the first phase of TRUST clinical trials for Crohn’s disease revealed that as per the results obtained thus far, the company was exploring looking at clinical developmental plans for TSO. The growth strategy, which the company has since focused on, is related to the recent rise in competition in this sector.

Coronado Biosciences Inc(NASDAQ:CNDO) hopes to see its plans to grow as part of a well –devised strategy. The company has indicated that it hoped to begin a new phase of product pipeline development. The company hopes to identify and then follow through with evaluation and finally look at licensing options such as in-licenses for products that will be of future interest for the company.

Coronado Biosciences Inc(NASDAQ:CNDO) is not averse to looking across the pharma platform for products. It is also interested in technologies, besides looking at a host of biotechology products, pharmaceutical companies as well as other hybrid solution providers.

Coronado Biosciences Inc(NASDAQ:CNDO) currently holds market cap of $89.50 million and trades on the stock market between infra-day price range of $2.00 and $2.21.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.